As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

In Australia, Ozempic is approved for the treatment of type 2 diabetes, while Wegovy is approved for weight management. Both ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

What is our current understanding of how differences in sex can affect obesity prevalence, comorbidities, and treatment options?

Glucagon-like peptide-1 ... semaglutide, modulate LS activity in patients with AUD. Additionally, the observed sex-specific effects in LS GLP-1R expression underscore the need for further ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally.